YHYigal Helviz

Yigal Helviz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yigal Helviz has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Sharon Einav

    Intensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Hebrew University Faculty of Medicine, Jerusalem, Israel

    8 shared publications
  • Sharon Einav

    Faculty of Medicine, Maccabi Healthcare System and Hebrew University, Jerusalem, Israel

    7 shared publications
  • Moshe Hersch

    General Intensive Care Unit, The Shaare Zedek Medical Center, Hebrew University Faculty of Medicine, Jerusalem, Israel

    4 shared publications
  • Moshe Hersch

    Intensive Care Unit, Shaare Zedek Medical Center, affiliated with the Faculty of Medicine, the Hebrew University of Jerusalem, Israel

    3 shared publications
  • Ariella Tvito

    Jesselson Integrated Heart Center, The Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9103102, Israel

    2 shared publications
  • Elad Asher

    2 shared publications

Latest Publications

  • Open Access

    Applying randomized control trial criteria to an ECPR cohort

    by Yigal Helviz, Frederic Shmuel Zimmerman, Amir Orlev, Michael Glikson, David Shimony, Daniel Fink, Refael Strugo, Elad Asher, Tomer Kaplan, Reem Naimy, et al.

  • Open Access

    Anemia before in-hospital cardiac arrest and survival from cardio-pulmonary resuscitation—a retrospective cohort study

    by Lior Shor, Yigal Helviz, Sharon Einav

    Background: Multiple patient-related variables have been associated with reduced rates of survival to hospital discharge (SHD) after in-hospital cardiac arrest (IHCA). As opposed to most of these, anemia may be reversible. This retrospective single-center study aims to examine the relationship between prearrest hemoglobin levels, comorbidities, and survival after cardiopulmonary resuscitation (CPR) among patients with non-traumatic IHCA. Patients were classified as anemic (hemoglobin < 10 g/dL) or non-anemic (hemoglobin ≥ 10 g/dL) based on their lowest hemoglobin measurement in the 48 h preceding the arrest. The primary outcome was SHD. The secondary outcome was return of spontaneous circulation (ROSC). Results: Of 1515 CPR reports screened, 773 patients were included. Half of the patients (50.5%, 390) were classified as anemic. Anemic patients had higher Charlson Comorbidity Indices (CCIs), less cardiac causes, and more metabolic causes for the arrest. An inverse association was found between CCI and lowest hemoglobin. Overall, 9.1% (70 patients) achieved SHD and 49.5% (383) achieved ROSC. Similar rates of SHD (7.3 vs. 10.7%, p = 0.118) and ROSC (49.5 vs. 51.0%, p = 0.688) were observed in anemic and non-anemic patients. These findings remained consistent after adjustment for comorbidities, in sensitivity analyses on the independent variable (i.e., hemoglobin) and on potential confounders and in subgroups based on sex or blood transfusion in the 72 h preceding the arrest. Conclusions: Prearrest hemoglobin levels lower than 10 g/dL were not associated with lower rates of SHD or ROSC in IHCA patients after controlling for comorbidities. Further studies are required to confirm our findings and to establish whether post-arrest hemoglobin levels reflect the severity of the inflammatory post-resuscitation processes.


  • Open Access

    Predictors of Hypoxemia and Related Adverse Outcomes in Patients Hospitalized with COVID-19: A Double-Center Retrospective Study

    by Rabea Asleh, Elad Asher, Oren Yagel, Tal Samuel, Gabby Elbaz-Greener, Arik Wolak, Ronen Durst, Eli Ben-Chetrit, Ran Nir-Paz, Yigal Helviz, et al.

    Hypoxemia is a hallmark of coronavirus disease 2019 (COVID-19) severity. We sought to determine predictors of hypoxemia and related adverse outcomes among patients hospitalized with COVID-19 in the two largest hospitals in Jerusalem, Israel, from 9 March through 16 July 2020. Patients were categorized as those who developed reduced (2) within the first 48 h after arrival to the emergency department. Overall, 492 hospitalized patients with COVID-19 were retrospectively analyzed. Patients with reduced SpO2 were significantly older, had more comorbidities, higher body surface area (BSA) and body mass index (BMI), lower lymphocyte counts, impaired renal function, and elevated liver enzymes, c-reactive protein (CRP), and D-dimer levels as compared to those with preserved SpO2. In the multivariable regression analysis, older age (odds ratio (OR) 1.02 per year, p < 0.001), higher BSA (OR 1.16 per 0.10 m2, p = 0.003) or BMI (OR 1.05 per 1 kg/m2, p = 0.011), lower lymphocyte counts (OR 1.72 per 1 × 103/μL decrease, p = 0.002), and elevated CRP (1.11 per 1 mg/dL increase, p < 0.001) were found to be independent predictors of low SpO2. Severe hypoxemia requiring ventilatory support, older age, and pre-existing comorbidities, including underlying renal dysfunction and heart failure, were found to be significantly associated with in-hospital mortality. These findings suggest that assessment of predictors of hypoxemia early at the time of hospitalization with COVID-19 may be helpful in risk stratification and management.


  • Open Access

    Lupus anticoagulant in patients with COVID‐19

    by Ariella Tvito, Eli Ben‐Chetrit, Frederic Shmuel Zimmerman, Elad Asher, Yigal Helviz


    • 1 March 2020
      • Vol. 22  (3) , 173-177

    A Retrospective Study of Short-term versus Long-term Use of High Flow Nasal Cannula after Extubation in the Intensive Care Unit

    by Yigal Helviz, Tehila Hajaj, Ayala Burger, Phillip D. Levin, Sharon Einav

    Background: The use of a high flow nasal cannula (HFNC) was examined for different clinical indications in the critically ill. Objectives: To describe a single center experience with HFNC in post-extubation critical care patients by using clinical indices. Methods: In this single center study, the authors retrospectively evaluated the outcome of patients who were connected to the HFNC after their extubation in the intensive care unit (ICU). At 48 hours after the extubation, the patients were divided into three groups: the group weaned from HFNC, the ongoing HFNC group, and the already intubated group. Results: Of the 80 patients who were included, 42 were without HFNC support at 48 hours after extubation, 22 and 16 patients were with ongoing HFNC support and already intubated by this time frame, respectively. The mean ROX index (the ratio of SpO(2) divided by fraction of inspired oxygen to respiratory rate) at 6 hours of the weaned group was 12.3 versus 9.3 in the ongoing HFNC group, and 8.5 in the reintubated group (P = 0.02). The groups were significantly different by the ICU length of stay, tracheostomy rate, and mortality. Conclusions: Among patients treated with HFNC post-extubation of those who had a higher ROX index were less likely to undergo reintubation.


  • The Use of High-Flow Nasal Cannula Oxygen Outside the ICU

    by Sasson Zemach, Yigal Helviz, Michal Shitrit, Reuven Friedman, Phillip D Levin

    BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy is a routine, evidence-based treatment in the ICU. Due to its ease of application, non–evidence-based use of HFNC has spread to non-ICU wards. This study reports on the experience with HFNC outside the ICU. METHODS: This is an observational study of HFNC prescribed by treating physicians in non-ICU areas. Primary outcomes included change in dyspnea visual analog scale score and physiological variables both before and 30 min after initiation of HFNC treatment. Secondary outcomes included mortality, ICU admission, and intubation. RESULTS: We observed decreased median (interquartile range) visual analog scale scores after initiation of HFNC: 8 (6–9) versus 5 (4–6) ( P < .001) in 90 of 111 subjects (81%, 95% CI 72.5–87.9%, P < .001). Breathing frequency (31 ± 10 vs 26 ± 7 breaths/min, P < .001) and saturation (84 ± 12% vs 94 ± 5%, P < .001) also improved. Overall cohort mortality was 55 of 111 subjects (50%); however, 41 of 111 subjects (33%) had a do not resuscitate (DNR) order. Among 70 non-DNR subjects, early mortality (< 72 h) occurred in 9 of 70 subjects (13%), and late mortality in 12 of 70 subjects (17%). The composite end point (ie, discharged alive, non-intubated, not admitted to ICU) was met by 35 of 70 subjects (50%) without a DNR order. An increased ROX index ([S pO 2 /F IO 2 ]/breathing frequency) was the only independent predictor associated with achieving the composite outcome (odds ratio 1.51, 95% CI 1.1–2.0, P = .01). Higher pre-connection visual analog scale score (odds ratio 1.75, 95% CI 1.35–2.28, P < .001) and a history of respiratory disease (odds ratio 3.52, 95% CI 1.27–9.72, P = .01) were predictors of greater improvement in dyspnea with HFNC. No variable predicted mortality. CONCLUSIONS: HFNC outside the ICU was associated with improved visual analog scale score, breathing frequency, and saturation but with a relatively high mortality, even in non-DNR subjects. HFNC was used in many subjects who had a DNR order. This therapy may have been palliative in intent. Care should be exercised in using this therapy in a setting that is not continuously monitored.


  • Open Access

    Effect of high-flow nasal therapy on dyspnea, comfort, and respiratory rate

    by Andrea Cortegiani, Claudia Crimi, Alberto Noto, Yigal Helviz, Antonino Giarratano, Cesare Gregoretti, Sharon Einav


  • Maternal cardiac arrest

    by Yigal Helviz, Sharon Einav

    The review is intended to serve as a practical clinical aid for the clinician called to maternal cardiac arrest. Anesthesia complications comprise an important cause of maternal cardiac arrest in developed countries Also predominant are hemorrhage and infections. Recent in-depth reports highlight fractionated care for pregnant women with cardiac and also probably neurological comorbidities. Pathology reports reveal a prevalence of thromboembolic phenomena that is higher than previously assumed but still rare. These are accompanied by particularly high mortality rates. The presenting rhythms of cardiac arrest which differ from most cardiac arrest populations, suggest the need for further in-depth investigation of both the causes and management of these cases. Despite these, outcomes are far better than those of most arrests. Key differences in treatment include are consideration of early airway management and possible medication complications. Pulseless electrical activity and VF should always alert to the possibility of hemorrhage. Echocardiography can diagnose thromboembolism. Also different are the need for Left uterine displacement and early delivery within after 4–5 min of initiation of resuscitation effort in cases with suspected compromise of the venous return or a poor likelihood of a good maternal outcome. Maternal cardiac arrest should be managed similarly to other adult cardiac arrests. At the same time its unique reversible causes require a different form of thought regarding diagnosis and treatment during the code.